<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571389</url>
  </required_header>
  <id_info>
    <org_study_id>Biocytics0001</org_study_id>
    <secondary_id>WIRB Protocol # 20070969</secondary_id>
    <nct_id>NCT00571389</nct_id>
  </id_info>
  <brief_title>Isolation and Culture of Immune Cells and Circulating Tumor Cells From Peripheral Blood and Leukopaks</brief_title>
  <official_title>A Study to Facilitate Development of an Ex-Vivo Device Platform for Circulating Tumor Cell and Immune Cell Harvesting, Banking, and Apoptosis-Viability Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCytics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carolina BioOncology Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioCytics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      This is a study to investigate the feasibility of harvesting, expanding in culture, and
      freezing circulating tumor cells and immune cells from cancer patients and healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Metastatic Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood cells, tumor cells, immune cells, plasma, discarded tissue (inc. tissue obtained from
      biopsies, paracentesis, pleuracentesis), leukapheresis products
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population of patients to be enrolled for this study will be adults (males and females)
        with histological proven metastatic solid tumors seen for routine cancer care at
        participating community cancer clinic sites. Patients on clinical trials with experimental
        study drugs will be allowed to participate in this observational pilot study.

        Healthy volunteers will also make up a portion of the study population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of metastatic stage IV or locally advanced (unresectable) stage
             III cancer of any solid tumor type. Patients may have been previously treated or chemo
             naïve or healthy volunteer

          -  Age &gt; 18yo

          -  Life expectancy &gt; 12 weeks

          -  ECOG Performance Status of 0, 1, 2, or 3 (Appendix 2)

          -  Screening laboratory values must meet the following criteria:

               -  WBC ≥2000/µL

               -  Neutrophils ≥1500/µL

               -  Platelets &gt;100x103/µL

               -  Hemoglobin ≥8 g/dL

               -  Creatinine &lt;2.5 x ULN

               -  AST ≤2.5 x ULN without, and ≤ 5 x ULN with hepatic metastases

               -  Bilirubin ≤2 x ULN (except patients with Gilbert's syndrome, who must have total
                  bilirubin &lt; 3.0 mg/dL)

        Exclusion Criteria:

          -  Primary Hematologic Malignancies (leukemia, lymphoma)

          -  Patients with any active infection requiring therapy (fever, localizing source) will
             be excluded until the infection resolves.

          -  History of, or a positive test for HIV-1, HIV-2, or HTLV-1 serum antibody, hepatitis B
             surface antigen, or hepatitis C positive RNA

          -  Underlying medical condition that, in the Principal Investigator's or treating
             oncologist's opinion, will obscure the interpretation of the patient's safety.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Powderly, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolina BioOncology Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Powderly, M.D.</last_name>
    <phone>704-947-6599</phone>
    <email>jpowderly@carolinabiooncology.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Balasco, CCRC</last_name>
      <phone>704-947-6599</phone>
      <email>abalasco@carolinabiooncology.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.carolinabiooncology.org</url>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2007</study_first_submitted>
  <study_first_submitted_qc>December 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage IV</keyword>
  <keyword>Advanced Stage III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

